| pubmed-article:8765410 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8765410 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:8765410 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:8765410 | lifeskim:mentions | umls-concept:C1514292 | lld:lifeskim |
| pubmed-article:8765410 | pubmed:dateCreated | 1996-9-17 | lld:pubmed |
| pubmed-article:8765410 | pubmed:abstractText | Interleukin 12 (IL-12) is a heterodimeric cytokine with a number of biological effects that are consistent with its potential role as an antitumor agent. The antimetastatic and antitumor activities of IL-12 have been demonstrated in a number of murine tumor models. Both the inhibition of established experimental pulmonary or hepatic metastases and a reduction in spontaneous metastases have been achieved by treatment with murine IL-12. Systemic treatment of mice bearing subcutaneous tumors with IL-12 results in tumor growth inhibition, prolongation of survival, and, in some models, tumor regression. The antitumor effect of IL-12 in these models is dose-dependent and can be initiated against well-established tumors. Mice cured of their tumor by IL-12 treatment are specifically immune to rechallenge with the same tumor. A series of experiments have demonstrated that both T-cells and interferon-gamma (IFN-gamma) induction are necessary for the optimal antitumor effects of IL-12. However, the antitumor efficacy of IL-12 has not been observed after exogenous administration of murine IFN-gamma, suggesting that additional factors may be important for the antitumor effects of IL-12. In several tumor models, IL-12 is more active or has a larger therapeutic window than either IL-2 or IFN-alpha, two cytokines with demonstrated antitumor activity against human malignancies. Combining IL-12 with other cytokines or chemotherapeutic drugs can improve antitumor effects. | lld:pubmed |
| pubmed-article:8765410 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8765410 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8765410 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8765410 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8765410 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8765410 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8765410 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:WrightR BRB | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:BrundaM JMJ | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:WiltroutR HRH | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:HendrzakJ AJA | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:PalleroniA... | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:WiggintonJ... | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:LuistroLL | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:AglioneAA | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:RumennikLL | lld:pubmed |
| pubmed-article:8765410 | pubmed:author | pubmed-author:DvorozniakMM | lld:pubmed |
| pubmed-article:8765410 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8765410 | pubmed:volume | 38 Suppl | lld:pubmed |
| pubmed-article:8765410 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8765410 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8765410 | pubmed:pagination | S16-21 | lld:pubmed |
| pubmed-article:8765410 | pubmed:dateRevised | 2005-11-16 | lld:pubmed |
| pubmed-article:8765410 | pubmed:meshHeading | pubmed-meshheading:8765410-... | lld:pubmed |
| pubmed-article:8765410 | pubmed:meshHeading | pubmed-meshheading:8765410-... | lld:pubmed |
| pubmed-article:8765410 | pubmed:meshHeading | pubmed-meshheading:8765410-... | lld:pubmed |
| pubmed-article:8765410 | pubmed:meshHeading | pubmed-meshheading:8765410-... | lld:pubmed |
| pubmed-article:8765410 | pubmed:meshHeading | pubmed-meshheading:8765410-... | lld:pubmed |
| pubmed-article:8765410 | pubmed:meshHeading | pubmed-meshheading:8765410-... | lld:pubmed |
| pubmed-article:8765410 | pubmed:meshHeading | pubmed-meshheading:8765410-... | lld:pubmed |
| pubmed-article:8765410 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8765410 | pubmed:articleTitle | Antitumor activity of interleukin 12 in preclinical models. | lld:pubmed |
| pubmed-article:8765410 | pubmed:affiliation | Department of Oncology, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA. | lld:pubmed |
| pubmed-article:8765410 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8765410 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8765410 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8765410 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8765410 | lld:pubmed |
